Introduction
Infl ammation is considered to play an important role in the development of type 2 diabetes as well as in further complications of the disease. At the cellular level, the expression of proinfl ammatory cytokines like interleukin (IL)-1 β and tumour necrosis factor (TNF) is implicated in insulin resistance and beta-cell failure (1). An enhanced infl ammatory activity is also detected in peripheral blood. It has been consistently shown in several clinical studies that the levels of infl ammatory markers such as C-reactive protein (CRP) and IL-6 are increased in patients with type 2 diabetes compared with healthy individuals, thus indicating a low-grade systemic infl ammation (1 -5). A few studies have also measured IL-1 β and TNF in the circulation but with less consistent results (3, 4, 6) , probably due to the fact that circulating levels of IL-1 β and TNF are oft en marginal. Instead, their major inhibitors, IL-1 receptor antagonist (Ra), TNFR1, and TNFR2, are readily secreted into the blood and considered reliable markers of activity of the cytokines (7 -9). Accordingly, elevated levels of IL-1Ra and TNFR2 in plasma have been associated with both insulin resistance and type 2 diabetes (10 -12). Interestingly, IL-1Ra levels also predict the incidence of type 2 diabetes independently of CRP levels and other risk factors (5,13). Moreover, circulating levels of TNFR2 predict morbidities such as cardiovascular disease and nephropathy in patients with type 2 diabetes (14,15).
Lifestyle interventions play a crucial role in the management of type 2 diabetes and may also lead to reduced infl ammation (1, 16) . Th e anti-infl ammatory eff ects have been attributed mainly to the concomitant weight loss, whereas the eff ects of interventional strategies alone, e.g. dietary change, have been more diffi cult to verify. Traditionally, a low-fat diet has been the recommendation for achieving weight loss and improved glycaemic control in type 2 diabetes. However, although still controversial, evidence is emerging that a low-fat, high-carbohydrate diet has less favourable metabolic eff ects compared with a low-carbohydrate diet or Mediterranean diet in subjects at high cardiovascular risk (17 -22) . Moreover, intake of carbohydrates, in particular refi ned carbohydrates, has been associated with a proinfl ammatory response (23 -25), whereas diets high in unsaturated and polyunsaturated fatty acids may decrease infl ammation (16, 22) .
By using a randomized study design, our aim was to investigate the eff ects of diet on systemic infl ammation in type 2 diabetes by comparing a low-fat diet (LFD) with a low-carbohydrate diet (LCD) during weight loss.
Material and methods
Th e study was performed in two primary health care centres in the south-eastern part of Sweden. Th e inclusion criteria were a diagnosis of type 2 diabetes treated with diet, with or without oral glucose-lowering medication or insulin. Exclusion criteria were diffi culties in understanding the Swedish language, severe mental disease, malignant disease, or drug abuse. Patients were randomized to advice to follow either a traditional LFD (aiming for 30 energy per cent, E%, from fat) or an LCD (aiming for 20 E% from carbohydrates) over 2 years, as recently described (20). Randomization was performed by drawing blinded ballots. Th e energy contents of diets were similar, 6694 kJ/day (1600 kcal/day) for women and 7531 kJ/day (1800 kcal/day) for men. Dietary advice was given by physicians on a group basis at baseline, 2, 6, and 12 months, and standardized in regard to energy content and nutrient composition. One dedicated dietician provided all participants with suitable recipes at each group meeting and was also available for questions from participants during the whole study period. Diet records from three consecutive days were performed at baseline, 3, 6, 12, and 24 months. Plasma samples were collected at baseline and 6 months, i.e. the time point when weight loss and compliance was maximal. Plasma samples were also collected from 41 control subjects in the same region, randomly invited from the Swedish Population Register. Subjects who accepted the invitation were included as controls if they were anamnestically healthy and received no medication. Anamnesis was gained by one dedicated nurse co-ordinator who also performed the blood sampling. None of the participants exhibited any clinical signs of acute infl ammation at the time of blood collection. Th e research protocol was approved by the Ethical Review Board of Link ö ping University. Written informed consent was obtained from all participants. Th e study was registered with trial number NCT01005498 at ClinicalTrials.gov.
Plasma C-reactive protein (CRP) was measured using an immunoassay (Roche Diagnostics GmbH, Vienna, Austria) with a detection limit of 0.03 mg/L. IL-6 and TNFRs were measured in plasma by ELISA assays (RnD Systems Europe, Abingdon, United Kingdom) with detection limits of 0.48 pg/mL (IL-6), 0.8 pg/mL (TNFR1), and 0.6 pg/mL (TNFR2). TNF, IL-1 β and IL-1Ra were analysed with Luminex (RnD Systems) with the detection limits 5.4, 2.8, and 7.9 pg/mL, respectively. Inter-assay coeffi cients of variation were 4.5%, 8.1%, 4.7%, 12%, and 11% for CRP, IL-6, TNFR1, TNFR2, and IL-1Ra, respectively.
IBM SPSS Statistics 19 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. Diff erences within and between groups were analysed with Student ' s paired and unpaired two-tailed t test except for infl ammatory markers that were not normally distributed. For CRP, IL-6, TNFR1, TNFR2, and IL-1Ra, MannWhitney U test was used for between-group comparisons diff erences and Wilcoxon signed ranks test for within-group comparisons. For correlation analyses Spearman ' s rank correlation was used. A linear multiple regression analysis was performed to assess the independent contribution of diff erent factors to changes in cytokine levels. Eff ects on weight and HbA1c levels were the main outcome variables. Th e original statistical power calculation that has been previously described (20) was based on an earlier 6-month pilot study of 28 participants with type 2 diabetes who were randomized to the same diets as in the present study. Twenty patients completed the study, and both diet groups achieved similar reductions in weight, while HbA1c levels tended to decrease in the LCD group only. Based on the results from the pilot study, the number of participants in the present trial was increased to at least 30 in each group.
Results

Study participants
Seventy-two patients were consecutively invited by the study nurses to participate. As shown in the fl ow diagram (Figure 1 ), 61 patients entered the study. No patients were lost to follow-up. Demographic and diabetes-related variables of patients in the two groups are presented in Table I . None of the participants were smokers. At baseline, 24 (77%) LFD patients and 22 (73%) LCD patients were treated with cholesterol-lowering drugs (statins).
Eff ects on metabolic parameters
Th e results of dietary records are shown in Table II . Adherence to the proposed diet was similar in both groups. However, the most prominent changes in nutrient intake were seen in the LCD group with a signifi cant reduction in E% intake from carbohydrates and a concomitant increase in E% intake from fat. At 6 months, the E% intake from fat:carbohydrate was 29:49 in the LFD group and 49:25 in the LCD group. Th e levels of body mass index, HbA1c, lipid levels and insulin doses at baseline and aft er 6 months are shown in Table III . Both groups showed a signifi cant reduction in body mass index. Also, the reduction in absolute weight was similar between groups and maximal at 6 months: LFD -4.0 (4.1) kg, LCD -4.3 (3.6) kg. Although benefi cial changes of HbA1c and HDL cholesterol levels were seen in the LCD group, the levels of HbA1c and HDL cholesterol remained similar between groups. Aft er 6 months, the total insulin dose was signifi cantly reduced in the LCD group but not in the LFD group, while the use of oral glucose-lowering medication did not change.
Eff ects on infl ammatory parameters
Th e levels of IL-1 β and TNF were below the limits of detection in all participants. Th e levels of CRP, IL-1Ra, IL-6, TNFR1, and TNFR2 at baseline and aft er 6 months are presented in Table IV . At baseline, no diff erences were seen between the two groups. Aft er 6 months, CRP levels did not show any signifi cant changes within the groups. IL-1Ra levels, on the other hand, decreased signifi cantly in the LCD group, while no change was seen in the LFD group. Th e levels of IL-6 increased in the LFD group only. Aft er 6 months, both IL-1Ra and IL-6 levels were signifi cantly lower in the LCD group than in the LFD group. TNFR1 levels did not change in any of the groups, while TNFR2 tended to increase in LFD patients ( P ϭ 0.064).
During the study period, statin therapy was initiated in two LCD patients, and, hence, 24 patients in each group were treated with statins at 6 months. At baseline, the levels of CRP, IL-1Ra, IL-6, TNFR1, and TNFR2 did not diff er signifi cantly between statin users ( n ϭ 46) and non-statin users ( n ϭ 15), neither did changes in infl ammatory markers diff er between statin and nonstatin users aft er 6 months. If the two LCD patients receiving statin during the study period were excluded from the analysis, the reduction of IL-1Ra remained signifi cant in the LCD group ( P ϭ 0.002). 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64   65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97  98  99  100  101  102  103  104  105  106  107  108  109  110  111  112  113  114  115  116  117  118  119  120  121  122  123  124  125  126  127  128 mono for print colour online
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Correlations between baseline variables and between changes during intervention
All infl ammatory markers were correlated with each other ( P values of at least 0.01). Moreover, all infl ammatory markers were signifi cantly correlated with BMI ( P values of at least 0.01). Levels of CRP, TNFR1, and TNFR2 showed correlations with insulin therapy as well as insulin dose ( P Ͻ 0.05), while levels of IL1Ra, TNFR1, and TNFR2 were correlated with HbA1c ( P Ͻ 0.05). Th e change in IL-1Ra during intervention was correlated with changes in BMI ( r ϭ 0.302, P Ͻ 0.05), HbA1c ( r ϭ 0.411, P Ͻ 0.01), CRP ( r ϭ 0.245, P Ͻ 0.05), and IL-6 ( r ϭ 0.266, P Ͻ 0.05) but not with changes in energy intake, HDL cholesterol, or insulin dose. Th e change in IL-6 correlated with change in CRP ( P Ͻ 0.05) but not with changes in energy intake, BMI, weight, HbA1c, HDL cholesterol, or insulin dose. In multiple regression analyses using change in IL-1Ra as dependent variable and changes in BMI, HbA1c, CRP, and IL-6 as independent variables, change in IL-1Ra remained associated with change in HbA1c only (standardized regression coeffi cient β ϭ 0.365, P Ͻ 0.05).
Comparison with a population without known diabetes
Forty-one clinically healthy subjects, 24 men and 17 women, all non-smokers (age 64 (7.9) years, BMI 25 (3.2) kg/m 2 ), were recruited as clinically healthy controls in order to provide ' reference ' levels of systemic infl ammatory markers. Th e levels in the controls were signifi cantly lower compared with the baseline levels in patients: CRP 0.73 (0.32 -1.19 ) mg/L, IL-1Ra 713 (569 -889) pg/mL, IL-6 1.34 (1.03 -2.22) pg/mL, TNFR1 1168 (1996 -2502) ng/mL, and TNFR2 2197 (1996 -2502) ng/mL, P values of Ͻ 0.05, Ͻ 0.001, Ͻ 0.001, Ͻ 0.001, and Ͻ 0.05, respectively. In the LCD group, the levels of IL-1Ra and IL-6 were still signifi cantly higher than in controls aft er 6 months, P Ͻ 0.05 and P Ͻ 0.01, respectively, while CRP had reached levels that were similar to controls (Table IV) .
Discussion
In the present study, we provide evidence that advice to follow a LCD reduces the subclinical proinfl ammatory state in type 2 diabetes. Despite similar weight loss and similar total energy intake in patients who were randomized to follow either LFD or LCD, cytokine levels were diff erently aff ected in the two groups. Aft er 6 months, IL-1Ra showed a signifi cant decrease in patients who were randomized to follow LCD, while IL-6 increased (and TNFR2 tended to increase) in those who followed LFD. Overall, these changes resulted in signifi cantly lower levels of IL-1Ra On the other hand, these authors observed a decrease in soluble adhesion molecules, like E-selectin, in the LCD arm only. Antiinfl ammatory eff ects of carbohydrate restriction have also been reported in animal models. Guinea pigs assigned to be fed LCD for 12 weeks showed signifi cantly lower levels of infl ammatory markers and oxidized cholesterol in the aorta compared with guinea pigs fed LFD (28). A carbohydrate-rich diet itself has also been associated with proinfl ammatory eff ects. A regimen of a 4-month eucaloric LFD in 22 healthy women resulted in unfavourable eff ects on infl ammatory markers including CRP and IL-6 (29). In the large Data are given as mean (SD). E% ϭ energy %; LCD ϭ low-carbohydrate diet; LFD ϭ low-fat diet.
and IL-6 in the LCD group compared with the LFD group at 6 months. Clinical studies investigating the eff ects of carbohydrate restriction on infl ammation are sparse, but results that are in line with our fi ndings have been reported. In one study, 40 overweight individuals with atherogenic dyslipidemia were randomized to ad libitum diets very low in carbohydrate (12%) or low in fat (24%) for 12 weeks. Both diets decreased the levels of infl ammatory proteins, but overall the anti-infl ammatory eff ect of carbohydrate restriction was larger in the very-low carbohydrate group than in the LFD group (26). A recent study by Davis et al. (27) compared LFD with LCD in 51 patients with type 2 diabetes and, in contrast to our results, did not fi nd any diff erences in IL-6 aft er 6 months.
PREDIMED Study, subjects at high cardiovascular risk were randomized to either two types of Mediterranean diet or a control diet (21). Th e control diet group who received advice to follow a low-fat diet reported 44 E% intake from carbohydrates which is rather close to the carbohydrate intake in our LFD group (49 E%).
In a minor sub-study of PREDIMED, the levels of IL-6 and soluble adhesion molecules decreased in the Mediterranean diet groups, while a signifi cant increase was observed in the control group after 3 months (30). In a larger sub-study of PREDIMED, the levels of IL-6, TNFR1, and TNFR2 decreased in the Mediterranean diet groups while TNFR1 and TNFR2 increased signifi cantly and IL-6 trended upwards in the control group aft er 12 months, thus supporting that advice to reduce fat intake, and thereby increase carbohydrate intake, is associated with proinfl ammatory eff ects (31). Notably, the PREDIMED Study showed a signifi cantly higher incidence of both type 2 diabetes and major cardiovascular events in the control group compared with the Mediterranean diet group aft er a median follow-up of 4 -5 years (19, 21) . Several mechanistic studies have reported that acute exposure to carbohydrates induces a proinfl ammatory response (1,16). Th is eff ect is also more pronounced in subjects with obesity or impaired glucose tolerance (32,33). In obese patients presenting for bariatric surgery, a history of high carbohydrate intake was associated with signifi cantly higher odds of infl ammation in the liver, while higher fat intake was associated with less infl ammation (34). Also, the type of carbohydrate may have a major infl uence on infl ammation. Both population-based and experimental studies have provided evidence that high intake of refi ned or simple carbohydrates is associated with proinfl ammatory eff ects (23 -25). In the LCD group of our study, the reduction in consumption of simple carbohydrates (monosaccharides, disaccharides, and saccharose) was more pronounced than the reduction in fi bre consumption, thus allowing us to speculate that this might have contributed to the lower cytokine levels.
Not only the nature of carbohydrates but also the nature of dietary fats can modulate infl ammation. Several studies have reported that a meal enriched in saturated fatty acids is followed by a proinfl ammatory response. On the other hand, diets high in unsaturated or polyunsaturated fatty acids have been associated with anti-infl ammatory eff ects (22, 30, 31) . Based on dietary records, we found no changes in the proportional intake of saturated, unsaturated, and polyunsaturated fatty acids in the LFD group over 6 months. In the LCD group, the percentage of energy intake from saturated fat showed a signifi cant increase, but, concomitantly, similar increases in intake of unsaturated and polyunsaturated fat were seen.
Th e reduction of IL-1Ra levels in the LCD group constituted the most prominent change in infl ammatory biomarkers. Th e reduction in IL-1Ra was also associated with a reduction in HbA1c aft er adjustment for weight reduction and changes in CRP and IL-6, indicating a close link between IL-1Ra and glycaemic control. In a previous study, Ruotsalainen et al. (9) used a broad panel of cytokines in order to examine whether levels were abnormal in 129 off spring of patients with type 2 diabetes. Interestingly, only the levels of IL-1Ra were elevated in normoglycaemic off spring and even more so in off spring with impaired glucose tolerance compared with healthy controls, suggesting that IL-1Ra is the most sensitive marker of cytokine response in the prediabetic state.
According to current guidelines, the majority of patients were treated with statins, which to some extent may aff ect the infl ammatory response. In vitro , statins exert a wide variety of anti-infl ammatory eff ects, and in randomized trials it is well documented that statins reduce plasma levels of CRP, whereas eff ects of cytokine levels are less evident (35). We did not fi nd any signifi cant association between changes in infl ammatory markers and statin therapy. However, it is still possible that diet-induced eff ects on CRP levels have been attenuated by the extensive use of statins in our study.
Advice to follow LFD or LCD had similar eff ects on weight reduction in our study. Th is is not in agreement with previous randomized studies reporting a greater weight loss with LCD than with LFD (36). One explanation may be that our aim was to achieve similar energy restriction in the two groups in order to focus on the eff ects of macronutrient composition. Accordingly, both groups also reported similar energy intake during the study.
One limitation of our study is the limited sample size and possible impact of other lifestyle-related factors, which is a methodological problem in any nutritional intervention. Th e patients were also informed of randomization results before the diet record at baseline was performed. Th is may explain why the reported intake of fat and carbohydrates diff ered between groups at baseline. Th e participants may already have started to adjust their diets according to allocated diet. No participants were lost to follow-up, which is a strength of the study. Th e fact that study nurses in the two primary health care centres had been responsible for the care of the participants ahead of the study start may explain this remarkably high participation rate.
Eff orts to reduce systemic infl ammation in patients with type 2 diabetes may be of utmost importance for the prevention of complications, such as cardiovascular disease and nephropathy. Carbohydrate restriction has been associated with anti-infl ammatory eff ects, but, still, evidence is insuffi cient to support specifi c amounts of carbohydrate and fat intake in individuals with type 2 diabetes, as stated by American Diabetes Association in their recently published recommendations for dietary therapy (37). Our fi ndings, however, indicate that the use of LCD aiming for 20 E% intake from carbohydrates may be an eff ective strategy to improve the subclinical infl ammatory state in type 2 diabetes.
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